Zhang, Wen Cai http://orcid.org/0000-0002-5274-527X
Skiados, Nicholas http://orcid.org/0000-0001-9661-4127
Aftab, Fareesa http://orcid.org/0000-0002-1202-1189
Moreno, Cerena http://orcid.org/0000-0002-3853-8223
Silva, Luis http://orcid.org/0000-0002-0178-5431
Corbilla, Paul Joshua Anthony
Asara, John M.
Hata, Aaron N. http://orcid.org/0000-0002-6127-318X
Slack, Frank J. http://orcid.org/0000-0001-8263-0409
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5P01CA120964, 5P30CA006516, K08 CA197389, P50CA196530, P50CA196530-03S1, R35 CA232105)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Ludwig Center at Harvard
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 17 December 2021
Revised: 15 June 2022
Accepted: 28 June 2022
First Online: 15 July 2022
Change Date: 25 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41417-022-00523-9
Competing interests
: ANH has received research support from Novartis, Relay Therapeutics, Pfizer, Roche/Genentech, Amgen, Eli Lilly, Blueprint Medicines, Nuvalent, Scorpion Therapeutics, and BridgeBio. ANH has served as a paid consultant for Nuvalent, EngineBio and Tolremo Therapeutics. The remaining authors declare no competing interests.